From screening chemical compounds to optimizing clinical trials to improving post-market surveillance of drugs, the increased use of data and better analytical tools such as artificial intelligence hold the potential to transform drug development, leading to new treatments, improved patient outcomes, and lower costs. However, several obstacles, particularly a lack of access to data, prevent the United States from achieving the full promise of data-driven drug development. Whether policymakers act to overcome these challenges will have a significant impact on both the well-being of Americans and the competitiveness of the United States.
ITIF's Center for Data Innovation released a new report exploring opportunities to accelerate data-driven innovation in drug development and hosted a panel discussion about the ways data can make drug development faster, more efficient, and lead to new cures.
Follow the discussion on Twitter with the hashtag #datainnovation.